For research and educational purposes only. Not medical advice.
Cotadutide Reference
Educational, not medical advice reference for Cotadutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule note…
Reference summary
The Phase 2a CKD trial (Parker 2022 Diab Obes Metab, PMID 35403793) reported reductions in albumin-to-creatinine ratio in adults with overweight or obesity plus chronic kidney disease. Earlier Phase 2 data in type 2 diabetes and obesity were also published. The program was discontinued before reaching Phase 3 outcome trials.
Regulatory and posture
- Categories
- GLP-1, Fat Loss
- Aliases
- MEDI0382, GLP-1 / glucagon dual receptor agonist
- Evidence posture
- human - Phase 2 data exist but AstraZeneca discontinued cotadutide development in 2023.
- Regulatory status
- Investigational. Cotadutide is a GLP-1 / glucagon dual receptor agonist that was in AstraZeneca development for obesity, type 2 diabetes, MASH, and chronic kidney disease. AstraZeneca discontinued the cotadutide program in 2023; active clinical development is no longer ongoing. There is no FDA-approved drug label.
- Content review status
- investigational verified
Selected public sources
- ClinicalTrials.gov cotadutide (MEDI0382) trial search
- PubMed: Parker et al. Diab Obes Metab 2022 - efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, in a randomized phase 2a study (PMID 35403793)
Related tools
- GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
- GLP-1 ramp planner - Preview a linear educational dose-step table.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
- GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
- Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.